Guided Therapeutics, Inc. (OTCMKTS:GTHP – Get Free Report) was the target of a significant decline in short interest in October. As of October 15th, there was short interest totalling 12,300 shares, a decline of 6.1% from the September 30th total of 13,100 shares. Based on an average trading volume of 2,600 shares, the days-to-cover ratio is presently 4.7 days.
Guided Therapeutics Price Performance
Shares of Guided Therapeutics stock opened at $0.16 on Thursday. Guided Therapeutics has a 1 year low of $0.06 and a 1 year high of $0.25. The firm’s 50-day moving average is $0.16 and its 200 day moving average is $0.13. The stock has a market cap of $9.76 million, a price-to-earnings ratio of -5.33 and a beta of 0.52.
Guided Therapeutics (OTCMKTS:GTHP – Get Free Report) last issued its earnings results on Wednesday, August 14th. The company reported ($0.01) earnings per share (EPS) for the quarter.
About Guided Therapeutics
Guided Therapeutics, Inc, a medical technology company, focuses on developing medical devices. It focuses on the commercialization of LuViva, a non-invasive cervical cancer detection device that identifies cervical cancers and precancers painlessly, non-invasively, and at the point-of-care by scanning the cervix with light, then analyzing the light reflected and fluorescent light.
Featured Stories
- Five stocks we like better than Guided Therapeutics
- What is the S&P/TSX Index?
- Zillow Stock’s Bull Case: Why This Recent Sell-Off Could Be a Buy
- What is the Nasdaq? Complete Overview with History
- IonQ’s Quantum Surge: Ride the Wave or Cash Out?
- 5 discounted opportunities for dividend growth investors
- Caterpillar Stock: Market Points to a Buying Opportunity
Receive News & Ratings for Guided Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Guided Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
